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Intravenous infusion of mesenchymal stem cells delays disease progression in 
the SOD1G93A transgenic amyotrophic lateral sclerosis rat model 
 
Running head: Mesenchymal stem cells delays progression of ALS 
 
Hirotoshi Magota 1, 2, Masanori Sasaki 1, 3, 4*, Yuko Kataoka-Sasaki 1, Shinichi Oka 1, 
Ryo Ukai 1, Ryo Kiyose 1, 2, Rie Onodera 1, Jeffery D. Kocsis 3, 4, Osamu Honmou 1, 3, 4 
 
1 Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, 
Sapporo Medical University School of Medicine, Sapporo, Hokkaido, 060-8556, Japan 
2 Tominaga Hospital, Naniwa-ku, Osaka-shi, Osaka, 556-0017, Japan 
3 Department of Neurology, Yale University School of Medicine, New Haven, 
Connecticut, 06510, United States of America 
4 Center for Neuroscience and Regeneration Research, VA Connecticut Healthcare 








Masanori Sasaki, M.D., Ph.D. 
Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, 
Sapporo Medical University School of Medicine, 
Sapporo, Hokkaido, 060-8556, Japan 





amyotrophic lateral sclerosis; neuroprotection; blood-spinal cord barrier; mesenchymal 
stem cell; intravenous 
 
Abbreviations: 
DAPI, 4ʹ,6-diamidino-2-phenylindole; DMEM, Dulbecco's modified Eagle's medium; 
FBS, fetal bovine serum; GFP, green fluorescent protein; MSCs, mesenchymal stem 
cells; PBS, phosphate-buffered saline; PBST, phosphate-buffered saline-0.1% Tween 
20; IV, intravenous; iSCI, ischemic spinal cord injury; BSCB, blood-spinal cord barrier; 
BBB, Basso, Beattie, and Bresnahan; EvB, Evans blue; NGS, normal goat serum; RNA, 
ribonucleic acid; SD, Sprague Dawley; PFA, paraformaldehyde; qRT-PCR: quantitative 
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ALS is a devastating neurodegenerative disease with few curative strategies. Both 
sporadic and familial ALS display common clinical features that show progressive 
paralysis. The pathogenesis remains unclear, but disruption of the blood-spinal cord 
barrier (BSCB) may contribute to the degeneration of motor neurons. Thus, restoration 
of the disrupted BSCB and neuroprotection for degenerating motor neurons could be 
therapeutic targets. We tested the hypothesis that an intravenous infusion of MSCs 
would delay disease progression through the preservation of BSCB function and 
increased expression of a neurotrophic factor, neurturin, in SOD1G93A ALS rats. When 
the open-field locomotor function was under 16 on the Basso, Beattie, and Bresnahan 
(BBB) scoring scale, the rats were randomized into two groups; one received an 
intravenous infusion of MSCs, while the other received vehicle alone. Locomotor 
function was recorded using BBB scoring and rotarod testing. Histological analyses, 
quantitative reverse transcription-polymerase chain reaction (qRT-PCR), were 
performed. The MSC group exhibited reduced deterioration of locomotor activity 
compared to the vehicle group, which displayed progressive deterioration of hind limb 
function. We observed the protection of motor neuron loss and preservation of 
microvasculature using Evans blue leakage and immunohistochemical analyses in the 
MSC group. Confocal microscopy revealed infused green fluorescent protein+ (GFP+) 
MSCs in the spinal cord, and the GFP gene was detected by nested PCR. Neurturin 
expression levels were significantly higher in the MSC group. Thus, restoration of the 
BSCB and the protection of motor neurons might be contributing mechanisms to delay 
disease progression in SOD1G93A ALS rats. 
